ERBB2 and breast cancer: In BC, two PARPi monotherapies, Olaparib and talazoparib, have been approved by the FDA and the European Medicines Agency (EMA) for deleterious or suspected deleterious gBRCA-mutated HER2-negative BC, based on the positive outcomes of the phase III trials OlympiAD and EMBRACA [30,66].